BU
BUWA.F Bio-Rad Laboratories Inc
- Market cap
- EUR 9.26B
- P/E
- 10.6x
- P/B
- 1.36x
- ROE
- 5.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BUWA.F undervalued?
Graham numberBUWA.F trades 19.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio-Rad Laboratories Inc fundamental analysis
No fundamental analysis for Bio-Rad Laboratories Inc yet.
Bio-Rad Laboratories Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins…
Full company profileBio-Rad Laboratories Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bio-Rad Laboratories Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.07B | 2.16B | 2.29B | 2.31B | 2.55B | 2.92B | 2.80B | 2.67B | 2.57B | 2.58B | 2.53B |
| Gross Profit | 1.14B | 1.19B | 1.22B | 1.26B | 1.44B | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B | 1.31B |
| Operating Income | 115M | 128M | 189M | 230M | 411M | 489M | 483M | 338M | 269M | 219M | 142M |
| EBITDA | - | 268M | 675M | 2.42B | 5.07B | 5.57B | -4.53B | -655M | -2.14B | 1.21B | 735M |
| Net Income | 28.1M | 122M | 366M | 1.76B | 3.81B | 4.25B | -3.63B | -637M | -1.84B | 760M | 404M |
| EPS | - | 4.10 | 12 | 59 | 128 | 142 | -123 | -22 | -66 | 28 | 15 |
| Balance Sheet | |||||||||||
| Total Assets | 3.85B | 4.27B | 5.61B | 8.01B | 13.0B | 17.8B | 13.5B | 12.3B | 9.36B | 10.6B | 10.8B |
| Total Liabilities | 1.26B | 1.34B | 1.59B | 2.25B | 3.09B | 4.11B | 3.89B | 3.56B | 2.79B | 3.12B | 3.18B |
| Shareholders' Equity | 2.59B | 2.93B | 4.02B | 5.76B | 9.88B | 13.7B | 9.62B | 8.74B | 6.57B | 7.45B | 7.60B |
| Cash & Short-term Investments | 456M | 384M | 432M | 661M | 662M | 471M | 434M | 404M | 488M | 530M | 465M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 216M | 104M | 285M | 458M | 585M | 670M | 194M | 375M | 455M | 532M | 404M |
| Capital Expenditure | 142M | 111M | 130M | 98.5M | 109M | 134M | 113M | 157M | 189M | 158M | 124M |
| Free Cash Flow | - | -11.2M | 156M | 359M | 476M | 657M | 194M | 218M | 266M | 375M | 280M |
| Ratios | |||||||||||
| ROE | 1.1% | 4.2% | 9.1% | 30.6% | 38.5% | 31.1% | -37.7% | -7.3% | -28.1% | 10.2% | 5.3% |
| ROA | 0.7% | 2.9% | 6.5% | 22.0% | 29.3% | 23.9% | -26.9% | -5.2% | -19.7% | 7.2% | 3.7% |
| Net Profit Margin | 1.4% | 5.7% | 16.0% | 76.1% | 149.5% | 145.3% | -129.5% | -23.9% | -71.9% | 29.4% | 15.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bio-Rad Laboratories Inc dividends
Bio-Rad Laboratories Inc has not paid dividends in the last 9 fiscal years.
Who owns Bio-Rad Laboratories Inc
- Insiders 16.30%
- Institutions 83.70%
- Public & others 0.00%
- Shares outstanding 21.8M
- Free float 21.5M
Bio-Rad Laboratories Inc company profile
- Company name
- Bio-Rad Laboratories Inc
- Ticker
- BUWA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 7,450
- Fiscal year end
- December
- Address
- 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
- Phone
- 510 724 7000
- Website
- bio-rad.com
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories Inc management
10- Mr. Norman D. SchwartzChairman & CEO · born 1950
- Mr. Jonathan P. DiVincenzoPresident & COO · born 1966
- Mr. Roop K. Lakkaraju CPAExecutive VP & CFO · born 1971
- Mr. James J. BarryExecutive VP & President of Life Science Group · born 1978
- Mr. Rajat MehtaExecutive Vice President of Global Commercial Operations · born 1979
- Mr. Ruben ArguetaVice President of Investor Relations
- Matthew WernerSenior VP and Chief Compliance & Privacy Officer
- Ms. Courtney C. EnloeExecutive VP, General Counsel & Secretary · born 1972
- Ms. Nanditha R. YelamanchiExecutive Vice President of Global Human Resources
- Mr. Michael CrowleyExecutive Vice President of Global Commercial Operations · born 1962